Bharat Biotech Partnered With IIL To Make Drug Substance For Covaxin

• ByStartupStory     |    May 29, 2021

Hyderabad-based Bharat Biotech had said it partnered with IIL to make the drug substance meant for COVID-19 vaccine Covaxin from June 15. It will dispatch the first batch to Bharat Biotech by July, according to the facility statement.

Director K Anand Kumar, Managing Director, said IIL to make drug substance for COVID-19 vaccine Covaxin, initially for two to three million doses per month.

This will be further scaled up to seven million later in the year, and eventually, to 15 million.

Kumar said IIL is converting its Karkapatla manufacturing unit into a Biosafety Level -3 (BSL3) facility for IIL to make the drug substance and also taking up construction of another block.

The technology transfer process was well underway, and IIL has the capabilities and expertise to manufacture inactivated viral vaccines at a commercial scale and under biosafety containment, the vaccine-maker said.

India records 1,73,790 lowest COVID cases count in last 45 days, taking India’s total tally of COVID-19 cases to 2,77,29,247, according to the Union Health Ministry data updated on Saturday.

Follow Startup Story